UNSPSC 51141563: Lacosamide

This classification denotes an anticonvulsant agent with the molecular formula C13H18N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 563KS2PQY5, chemically known as 2-(acetylamino)-3-methoxy-n-(phenylmethyl)propanamide, (2r)- but generally known as lacosamide, which bears US NIH Compound Identifier 219078. European Medicines Agency schedules Lacosamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25407.

UNSPSC 51141563 Lacosamide is a Commodity code. State and local governments buying under this code are actually procuring pharmaceutical products—primarily generic multi-source medications and over-the-counter (OTC) products for public health systems, as well as specialized pharmaceutical supplies such as naloxone and drug deactivation systems for community health initiatives. The issuing bodies span state health and human services agencies, county health departments, and cooperative purchasing alliances serving multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, has established itself as a significant aggregator, bringing together state and local government facilities across participating states including Oregon. Seminole County, Florida, and the Texas Health and Human Services Commission also appear as active buyers, though the code shows limited concentrated repeat activity in the recent opportunities block.

Geographic activity centers on Minnesota (through MMCAP's multi-state cooperative), Florida, and Texas, with the cooperative purchasing model extending reach across additional states. The Minnesota Department of Administration issued an RFP for generic multi-source pharmaceuticals and OTC products through MMCAP with a response deadline of March 26, 2026, requiring vendors to supply products through three authorized wholesalers and seeking competitive pricing on fixed-price, net-price, and WAC-minus models. Seminole County, Florida, posted an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, with quarterly deliveries to the county's community health building. The Texas Health and Human Services Commission issued an RFI on April 3, 2026, exploring direct-to-manufacturer prescription contracting capabilities, signaling early-stage procurement planning rather than immediate award opportunity. All three solicitations emphasize compliance with federal pharmaceutical regulations, Good Manufacturing Practices certification, and Drug Supply Chain Security Act adherence.